Momelotinib FDA approval date

The FDA approved Momelotinib (OJJAARA) on 15 Sep 2023.

FDA approval date
15 Sep 2023

Drug identity checked against registry records

Also recorded as OJJAARA

Included trials

TrialSponsorPhaseStatusPrimary completion
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate ThrombocytopeniaNCT05980806KPTIPhase 2Recruiting2027-06Estimated

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2023-09-15DayMomelotinibFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "NDA216873", "applicant_as_listed_by_fda": "GLAXOSMITHKLINE", "brand_names": ["OJJAARA"], "active_ingredients": ["MOMELOTINIB DIHYDROCHLORIDE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20230915", "matched_on": "registry alias equals FDA brand name and drug name is its active ingredient"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026